MYD88 Mutation Analysis

Last Modified: 3/3/2020 9:01:30 AM


Specimen Requirements:

FFPE tissue: Paraffin block
Collection Instructions: Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Transport & Storage: Temperature/Stability: Refrigerate, and use cold pack for transport, cold pack should not be in direct contact with specimen.
Reference Range: Refer to Interpretive Results
Methodology: Molecular
Clinical Significance: MYD88 mutation is the most common genetic abnormality in the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL), detected in 40% of cases. Mutations are rare in the germinal center B-cell-like (GCB) subtype, so mutation analysis can be useful to differentiate between the ABC and GCB subtypes. The L265P mutation is present in >90% of Waldenstrom's macroglobulinemia (WM) and has been associated with increased risk of progression to WM in IgM MGUS patients. MYD88 is also implicated in susceptibility to BTK inhibitors in the treatment of B-cell neoplasms. Testing is available separately or in combination with three other contributory genes in the BTK Inhibitor Primary Susceptibility Panel.
Custom Panel: No

PRODUCTION SCHEDULE

Turn Around Time: 7 to 8 days
Sites Performed: NeoGenomics
PHL Test Code: PS
EPIC Test Code: N/A
Send Out Test Code: Soft Path - MYD88
Alternate Test Names: Myeloid Differentiation Primary Response 88
CPT Coding: 81305

Go back to the top of the page.